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Background: Hepatitis B virus (HBV) surface antigen (HBsAg) screening in blood banks reduced the risk of HBV
transmission through transfusion. However, the detection of occult HBV infection among blood donors is
imperative for improving blood safety. The aim of this study was to determine the frequency of occult hepatitis B
virus infection among blood donors in Medellin, North West Colombia and to characterize the viral genotypes and
mutations.
Methods: Serum samples from blood donors with the serological profile HBsAg-/Anti-HBc+ were evaluated by
nested or hemi-nested PCR for HBV genome ORF C, ORF S and ORF X. A pairwise analysis was carried out with
deduced amino acids sequence of overlapping S/P region.
Results: A total of 302 serum samples HBsAg-/Anti-HBc+ from donors recruited in a blood bank in Medellin were
evaluated by PCR for the HBV genome. Six samples (1.98%) were identified as occult HBV infection. The cases were
confirmed by sequencing and viral load analysis. All HBV strains were genotype F, subgenotype F3. The amino acid
substitutions sY100H, sV184A, and sK141N were detected in ORF S and rtL108P, rtR110G, rtL180M, rtR192C, rtT150S,
and rtL187V in ORF P.
Conclusions: This is the first report and characterization of OBI cases in blood donors in Colombia. Six from 302 donors
HBsAg-/Anti-HBc+were identified. The mutations rtL108P, rtR110G, rtR192C, rtT150S and rtI187V were characterized for
the first time in these samples. Further studies are necessary to explore if these mutations could potentially impair HBsAg
production.
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In the last three decades a new type of HBV infection
has been recognized, Occult HBV infection (OBI). This
clinical entity is diagnoses by detection of the HBV gen-
ome (HBV-DNA) in liver tissue and/or serum samples,
in the absence of detectable hepatitis B virus surface
antigen (HBsAg). Additionally, OBI is characterized by a
very low viral load (<200 IU/mL) and detection of the
antibodies anti-Core (anti-HBc) in 80% of the cases.
Moreover, in 20% of the cases there is no evidence of
any HBV serological marker [1].* Correspondence: maria.navas@udea.edu.co
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article, unless otherwise stated.OBI is recognized as a disease with important clinical
implications, including the risk of HBV transmission by
blood transfusion and organ transplantation and pro-
gression to cirrhosis and/or Hepatocellular carcinoma
(HCC) [2]. It is proposed that the development of OBI
may result from a multifactorial process involving viral
and host factors. The hypotheses of OBI pathogenesis
include mutations in viral genome, negative regulation
of replication by epigenetic mechanisms and/or coinfec-
tion with hepatitis C virus (HCV) or Human Immuno-
deficiency Virus (HIV) [3].
Transfusion-transmitted HBV infection was demon-
strated early in 1978, through blood components from
HBsAg negative donors, in developing countries where
the prevalence of HBV is higher and the procedures for
blood donor selection and screening for infection markersentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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fication testing (NAT) has been introduced as important
serum testing for HBV infection in order to improve
blood safety [5-7].
The prevalence of OBI found in different studies range
widely from less than 1% to as high as 90%. The preva-
lence rates might be accounted by differences in study
populations and techniques for detection of the HBV
genome [3,8].
In Colombia, there are few reports of OBI. In a cohort
of 50 HIV-1 patients, 12 (8.3%) individuals were classi-
fied with a serological profile HBsAg-/anti-HBc+; in an-
other study the frequency of OBI reported was 1% in
103 HIV-1 patients [9,10]. On the other side, Beltran et
al analyzed 129 HBsAg-/anti-HBc+ samples obtained
from Colombian blood donors in serum pools using
NAT; the frequency of OBI reported in this study was
0% [11].
The aim of this study was to determine the OBI fre-
quency and to characterize the viral genotypes and mu-
tations in samples from blood donors with serological
profile HBsAg-/anti-HBc+ attending a reference blood
bank in Medellin city.
This study provides new information regarding the OBI
in blood donors in Colombia and data of HBV strains mo-
lecular characterization circulating in the study population.
Results
Study population
In a reference blood bank in Medellin city, 14.345 altru-
istic blood donations were received between February
and September 2011 through campaigns conducted in
people living in Antioquia state, North West Colombia.
The 34.5% of blood donations correspond to first time
blood donor.
A total of 29/14.345 cases of HBV infection (0.2%)
were identified by detection of HBsAg; however, 310/
14.345 (2.16%) blood donors showed a serologic profileTable 1 Serological profile of donors attending a reference B
September 2011
Month Blood donors First time blood do
February 1819 452 (24.8)
March 1984 922 (46.5)
April 1744 635 (36.4)
May 1815 691 (38.1)
June 1778 589 (33.1)
July 1716 519 (30.2)
August 1894 590 (30.9)
Septiember 1595 552 (34.6)
Total 14345 4950 (34.5)HBsAg-/anti-HBc+ (Table 1). According to the technical
norms for procedures in blood centers in Colombia, all
blood units positive for any serological marker are
discarded.
Serum samples from 302 blood donors HBsAg-/anti-
HBc+ were included in this study. Data of Alanine Ami-
notransferase and bilirubin levels in the OBI cases was
not available. None of the 302 samples was positive for
anti-HCV or anti-HIV-1 or 2. The mean age of the study
population was 39.7 ± 10.97 years; 56% of the subjects
were male and 44% female. The information of ethnicity
is not included in the interview for donor selection.
HBV DNA amplification
Six samples from 302 were positive for HBV DNA (ORF S)
(Figure 1). In these cases, it was possible to amplify a region
of 336 nucleotides (nt 422 to nt 758), corresponding to
small region of the HBsAg.
These serum samples were subsequently evaluated by
hemi-nested PCR of HBV Core region (promoter and
ORF Core) and ORF X. One from 6 samples was also
positive for HBV DNA ORF X. The ORF Core region
was not successfully amplified in any sample (data not
shown). The viral load of the 5 serum samples ranged
between 18.4 and 224.3 IU/mL. In one case, the viral
load was >4.000 IU/mL
Regarding the serological marker anti-HBs, the six
samples identified as OBI were positive for anti-HBs.
According to the results, 3 donors had anti-HBs titers
≥110 mUI/ml and 3 donors ≤110 mIU/ml (Table 2). The
data of HBV vaccination was not available.
HBV genotypes
Phylogenetic analyses were conducted by aligning the 6
sequences identified in this study with sequences of HBV
genotypes (A to I) available in GenBank (Table 3). After
editing of the sequences, it was considered for each one
an informative fragment of 267 nt, corresponding to smalllood Bank in Medellin, during the period February to
Serological profile
nors (%) HBsAg+ HBsAg-/anti-HBc+ (%)
4 (0.22) 30 (1.65)
4 (0.20) 25 (1.26)
4 (0.23) 61 (3.5)
1 (0.05) 12 (0.66)
2 (0.11) 40 (2.25)
4 (0.23) 61 (3.55)
6 (0.32) 73 (3.85)
4 (0.25) 8 (0.5)
29 (0.20) 310 (2.16%)
500bp
100bp
MW      PC       001      024      038      091       097      123      NC1     NC2 
Serum samples HBsAg-/Anti-HBc+
Figure 1 HBV ORF S detection in serum samples from blood donors with serologic profile HBsAg-/anti-HBc+. Amplification of small
region ORS S (nt 422 to nt 758). MW: molecular weight marker, PC: Positive control serum sample (viral load 50000 IU/mL), NC: negative control
PCR 1st and 2nd round, bp: base pairs.
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were grouped in genotype F clade, subgenotype F3 using
the NJ method. The bootstrap values for the genotype and
cluster branching were obtained from 1000 replicates
(Figure 2). Congruent topologies were found between the
phylogenetic trees obtained by the ML, MP and, MrBayes
methods (data not shown).
Mutations in the overlapping ORF S/P
The 6 sequences of HBV isolates were aligned and com-
pared with the sequences EF397971, EF397973, FJ589066,
DQ899149 and AB036905 genotype F, subgenotype F3Table 2 Molecular and serological characteristics of OBI cases
Medellin, Colombia
Serological profile
Code HBsAg anti-HBc anti-HBs (mIU/mL)
001 Negative Positive 105.6
024 Negative Positive 108.9
038 Negative Positive 24.5
091 Negative Positive 291.4
097 Negative Positive 672.7
123 Negative Positive >1000.0reported in GenBank (Table 3) to identify mutations
in ORF S and ORF P [12]. Synonymous and non-
synonymous mutations were identified in the ORF S of 4
OBI isolates (Table 4). Regarding the ORF P, it was pos-
sible to identify nonsynonymous mutations in the se-
quence coding for the RT domain, three of them were
identified in the same sample (Table 4).
The deduced amino acid sequences were also analyzed.
In the coding region of HBsAg, three amino acid substitu-
tions were identified, sY100H, sV184A and sK141N in
samples 001, 024 and 038, respectively (Figure 3); these
changes correspond to the mutations T1387C, T1640Cin blood donors attending a reference Blood bank in
Virological characteristics







Table 3 Sequences of HBV including in phylogenetic
analysis
GenBank Code Year Country Genotype Subgenotype
DQ899149 2006 Venezuela F F3
HM467784 2010 Colombia F F3
FJ657521 2009 Argentina F F1b
FJ589065 2008 El Salvador F F1a
AY311369 2003 Venezuela F F2
DQ899145 2006 Venezuela F F2
FJ657520 2009 Argentina F F4
FJ657519 2009 Argentina F F4
FN821462 2010 Madagascar A -
AB602818 2005 Japan B -
AB540582 2010 Indonesia B -
AB540583 2010 Indonesia C -
AB540585 2010 Indonesia C -
AB267090 2006 Japan D -
EF690482 2007 Brazil D -
AB091257 2002 Costa de Marfil E -
AP007262 2004 Japan E -
AP007264 2004 Japan G -
AB191378 2004 Japan G -
AP007261 2004 Japan H -
AB516395 2009 Mexico H -
FJ023663 2008 Laos I -
FJ023661 2008 Laos I -
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we identified three amino acid substitutions in sample 001
(rtL108P, rtR110G and rtL180M). Additionally, rtR192C,
rtI187V and rtT150S substitutions were observed in sam-
ples 024, 038 and 123, respectively (Figure 4).
Discussion
Colombia has a heterogeneous prevalence pattern of Hepa-
titis B virus infection, including regions of high, moderate
and low prevalence. According to the Colombian National
Health Institute, 2.366 cases of HBV infection was reported
in 2013 corresponding to an average incidence of 4.67/
100.000 inhabitants while the incidence in Antioquia state
was 6.07/100.000 for the same period [13].
Antioquia state is one of the most important regions
in Colombia due to area (62.840 kms2), inhabitants
(5.988.458) and industrial development [14]. Medellin,
capital of this state, is the second most important city of
the country.
The Colombia Health Minister and the National Insti-
tute of Health implemented in 1993 the laboratory
screening of blood donations, including the serological
marker of HBV infection, HBsAg. Until 2012, HBsAgwas the only required test for HBV infection; after that it
was introduced another marker of HBV infection, antiHBc.
Since February 2014, the blood banks in Colombia must
discard donations reactive for HBsAg and/or anti-HBc [15].
Actually, 36% of blood units collected before 2011 in
Colombia were not being screened for anti-HBc and only
8% were analyzed for detection of nucleic acids by NAT in
pools of six units per test [11]. One of the blood banks
using screening the anti-HBc in donors since 2000 is the
reference blood bank of this study.
The lack of anti-HBc in the test for blood donor is an
important risk of HBV transmission from occult hepa-
titis B infection cases. In Colombia, there are no data
about OBI prevalence in blood donor except for the re-
port of 0% of OBI cases in 129 HBsAg-/anti-HBc +
serum samples analyzed by NAT in serum pools [11].
The present study is the first one identifying and char-
acterizing OBI cases in blood donors in Colombian do-
nors. The criteria for the diagnosis of OBI in the present
study were: i) serological profile markers HBsAg-/anti-
HBc+, ii) HBV DNA detection by nested or hemi-nested
PCR, iii) sequencing of HBV strains, and iv) viral load
<200 IU/mL.
Consequently, it was possible to identified 6 (1.98%)
cases of OBI from 302 blood donor samples. Although,
the sample 123 showed a viral load of 4638 IU/mL, the
case was classified as OBI considering the first three cri-
teria; additionally, HBV escape mutants was not identi-
fied in this sample.
The frequency 1.98% is quite similar compared with
other studies carried out in blood donor from other Latin
American countries with similar epidemiological pattern
of HBV infection. In a recently study, the prevalence of
OBI was determined in a population of 799 blood donors
anti-HBc + living at the State of Amazonas, Brazil, a re-
gion of high endemicity for HBV infection. Eight samples
(2.7%) were classified as OBI in the study population [16].
In a previous study carried out in Recife, Northeastern
Brazil, the frequency of OBI was estimated in 2.5% from
120 samples of blood donors anti-HBc + [17]. However, in
two studies of blood donors in Porto Alegre and in
Campinas, Southern Brazil, the frequency of OBI was 0%
and 6%, respectively [18,19]. The results of these studies
could be related to the differences of HBV endemicity be-
tween Northern and Southern states of Brazil.
Additional data of OBI in Latin American showed 4.3%
OBI cases from 258 HBsAg-/anti-HBc+ samples from
blood donors in Caracas, Venezuela, and 6.4% OBI cases
from 372 blood donors with serological pattern HBsAg-/
anti-HBc + in Yucatan, Mexico [20,21].
On the other side, a high frequency of OBI was described
in an Amerindian community in Venezuela; this population
has exposure to HBV but low frequency of HBsAg (17%)
compared with other amerindian comunities in this country.
Figure 2 HBV ORF S phylogenetic tree without root. For the analysis, it was used a fragment of 267 nucleotides, corresponding to small
region of ORFS (nt 449 to nt 716). The sequences of the OBI cases (indicated by red dots) were compared with representative sequences of all
HBV genotypes (A to I). Tree was generated by MEGA 5.0 program using Neighbor Joining method. Bootstrap values (indicated with Arabic
numerals) were obtained from 1000 replicates, values above 50 are indicated. The green diamond indicates the positive control.
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from individuals of the Piaroa community HBsAg-/anti-
HBc+ or HBsAg-/anti-HBc-. The high frequency of OBI
(32.8%) described in this population could be related to
immunosuppression due to multiple parasitic and bacter-
ial infections [22].
Other studies of HBV infection carried out in Amerindian
population showed lower prevalence of OBI compared to
the frequency described in Piaroa community in Venezuela.Table 4 Mutations in ORF S and ORF P in OBI cases from bloo
Code ORF S
Synonymous mutations* Non syn






A. Adenine; G. Guanine; T. Thymine; C. Cytosine.
*Mutations regarding to sequences EF397971, EF397973, FJ589066, AY311370, DQ8The prevalence of OBI reported in Nahuas and Huichol
communities from Mexico was 14.2% (41/289) [23]. While
the prevalence of OBI in 487 individuals from the Inuit
community in North American was 9.7% [24].
In another study of HBV infection in Ameridian com-
munities belonging to four ethnic groups in Argentina
(Mbyá-guaraníes, Kollas, Wichis and Sagua-Huarpes) 11
cases of OBI was identified from 59/561 amerindians re-
active for HBsAg and/or anti-HBc [25].d donors
ORF P










Figure 3 HBsAg deduced amino acid (aa) alignment. Comparison of aa substitutions in the Major Hydrophilic Region (MHR) of the HBsAg (aa
99-187), between sequences from OBI samples 001, 024, 038, 091, 097 and 123 and sequences from chronic HBV carriers subgenotype F3 from
Colombia and Venezuela reported in GenBank. The aa were presented in single letter code. The lines indicate the regions of the sequences not
included in the analysis. SueroCntP 11 corresponds to the positive control. At the top of the alignment, it is represented the MHR by rectangles
between aa 107-165 of the HBsAg and the "a" determinant (aa124 to aa147). Red arrows indicate epitopes recognized by cytotoxic
T lymphocytes.
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to the prevalence of HBV infection in the study popula-
tion and the sensitivity of HBV DNA assays. In areas
with intermediate to low prevalence of HBV infection, it
is expected less than 5% of OBI cases in blood donors
with serological profile HBsAg-/anti-HBc+; on the other
side, it high prevalence regions of HBV infection, the
OBI cases is estimated between 5% to 25% among the
blood donors HBsAg-/anti-HBc + [26].
All HBV strains from OBI cases in this study belonged
to genotype F, subgenotype F3 as indicated by the phylo-
genetic analysis (Figure 2). This result is consistent with
the epidemiological data in Colombia, where the subge-
notype F3 is the most common in HBV infected patients
and blood donors [12,27,28].
Indeed, the genotype F, subgenotype F3, was the most im-
portant HBV genotype described in two studies carried out
with samples from blood donors in Colombia. In the first
one, the genotype F was identified in 86% of the samples ofFigure 4 HBV polymerase deduced amino acid (aa) alignment. Compa
sequence subgenotype F3 reported in GenBank. Substitutions were identifi
in single letter code. The lines indicate the regions of the sequences not in
control. At the top of the alignment, it is represented by rectangles the OR
to G motives describe in the HBV polymerase.blood donors in Bogota and Bucaramanga cities, while the
genotypes A, D, C, G were identified in 14% of the samples
[12]. In the second one study carried out with samples from
blood donors of different cities around the country, the
genotype F was also the predominant (77%); however, the
genotypes A and G were identified in 15% and 7.7% of
the samples, respectively [27]. The predominance of HBV
genotype F, subgenotype F3 (83.3%), was also described in
patients with end-stage hepatic disease attending a hospital
in Medellin city [28].
Interestingly, the genotype F, subgenotype F1b, was
the only one identified in Amerindian communities liv-
ing in Amazonas state, south east of Colombia [29].
The circulation of different HBV genotypes could be re-
lated to the numerous ethnic groups present in this country.
Indeed, the estimated admixture population in Colombia is
American ancestry 0.29, European Ancestry 0.6 and African
Ancestry 0.11; although, African ancestry is highest in the
Pacific and Atlantic regions (particularly on the Pacific)rison of aa sequences of OBI samples with chronic HBV consensus
ed on RT polymerase domain (aa rt107-rt195). The aa were presented
cluded in the analysis. SueroCntP 11 corresponds to the positive
F P and their domains between aa 1 to 845. Red arrows indicate the A
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while, American ancestry is highest in the south of the
country [30].
Three non-synonymous mutations were detected in
OBI cases; Mutations in the S region T1387C, T1640C,
and A1512T and the amino acid substitutions sY100H,
sV184A, and sK141N, respectively. Two of these muta-
tions (sV184A and sY100H) were found outside of the
HBsAg Major Hydrophilic Region (MHR) and therefore
outside of the “a” determinant (Figure 3).
Amino acid changes at residue 100 of HBsAg are a
frequent event in OBI cases. Indeed, the substitution
sY100Cysteine (C) have been described in different studies
of OBI cases in blood donors [31], in HIV infected patients
[32] and in patients undergoing hemodialysis [33]. Addition-
ally, the mutation sY100Serina (S) was detected in samples
from OBI cases [34].
As shown, the 100-residue in HBsAg is often variable
in cases of OBI. Cysteine (C), serine (S) and histidine
(H) are polar amino acids, and thus it is suggested that
the change of this three amino acid can have a similar
effect on the antigenicity of the HBsAg. However, further
studies are necessary to confirm the frequency of those
mutations in OBI cases and its consequence on the syn-
thesis level and antigenicity of the HBsAg.
Huang et al, carried out the molecular characterization
of HBV from OBI cases in a cohort of blood donors
(n = 38.499). The analysis of the ORF S showed a higher
frequency of mutations in MHR (aa 110–160) in OBI
cases compared to the donor HBsAg + (Chronic infec-
tion). Interestingly, the MHR mutation frequency was
not correlated with the serum level of HBsAg. Thirteen
MHR mutations (G119R, P120T, C124R, C124Y, I126S,
Q129R, S136P, C139R, T140I, K141E, D144A, G145A,
and G145R) were detected and functionally character-
ized in vitro and in vivo. Some of these mutations, in-
cluding K141E, impaired the secretion of virions and
subviral particles and reduced the reactivity of antibodies
anti-HBs used in immunoassays [35]. In the present
study was also described a mutation at position 141
(sK141N).
Six amino acid substitutions rtL108P, rtR110G, rtL180M,
rtR192C, rtT150S and rtI187V were detected in the se-
quence of 4/6 OBI cases, three of them were present in
sample 001. The mutations were found in the reverse tran-
scriptase (RT) domain of the viral polymerase (nucleotides
349 to 692).
The rtL180M substitution has already been reported
in the literature. Moreover, the change of Leucine to
Methionine has been described in association with other
mutations in the YMDD polymerase domain, in particu-
lar with the substitutions rtM204V and rtM204I, related
to interferon resistance and polymerase protein dysfunc-
tion [36,37]. However, in this study it was not possibleto analyze the sequence coding the YMDD domain, be-
cause the size of the fragment analyzed (only 267 nucle-
otides) it was no enough. Interestingly, other studies
have shown the emergency of mutations in the ORF S
that also caused mutations in the ORF P. Lai et al, dem-
onstrated that mutations sL173F, sI195M, and sY200H
also related to these mutations rtA181V, rtM204V, and
rtV208A, all of them associated to interferon resistance.
However, in the present study we did not identified mu-
tations in the ORS S overlapping to the ORF P or vice-
versa [38].
This is first report of the mutations rtL108P, rtR110G,
rtR192C, rtT150S and rtI187V. Further studies are neces-
sary to characterize in vitro and in vivo these mutations
and its effects on antigenicity and on HBV replication.Conclusion
The Colombian National Institute of Health is the institu-
tion responsible for the blood system and the strategies and
policies for safe blood in this country. Recently, it was in-
cluded the marker anti-HBc in the official regulation for
blood screening donations. The anti-HBc is an important
serological marker for detection of cases of OBI and for re-
ducing the residual risk of HBV transmission.
In this study for the first time in Colombia, we identify
and characterized OBI cases in blood donors by molecular
and serological tests. A frequency of 1.98% of OBI cases
was found in 302 blood donors HBsAg-/anti-HBc+ attend-
ing a reference blood bank in the second most important
city of Colombia. Additionally, three nonsynonymous mu-
tations were found in the ORF S, S region, T1387C,
T1640C, and A1512T; whereas 6 amino acid substitutions
(rtL108P, rtR110G, rtL180M, rtR192C, rtT150S and
rtI187V) were found in the RT domain. Some of these mu-
tations could be related to the pathogenesis of OBI.
This data is important for the Colombian Blood system
and the epidemiology of HBV infection in Colombia and
in Latin America. Further studies of OBI in blood donors
from different geographical regions in Colombia are ne-
cessary considering the endemic patterns of HBV infec-
tion in this country.Methods
Serum samples
This study was performed between February and Septem-
ber 2011, among blood donors from a representative blood
bank of Medellin. Units of blood components were indi-
vidually screened for HBsAg and anti-HBc using commer-
cial Kits (Bioelisa HBsAg 3.0 Biokit and anti-HBc Biokit).
The detection limit of the HBsAg assay is 0.100 units/mL
(standards Paul Ehrlich Institute, Germany) and 0.125
IU/mL (International standards from the World Health
Organization (WHO ref. 80/549) [39].
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HBsAg-/anti-HBc+ were identified. Samples were an-
onymous and identified only by alphanumerical codes,
after signing the informed consent provided by the blood
bank. The protocol was approved by the ITM ethical
committee.
Detection and quantitation of HBV-DNA
Total DNA was extracted from 200 μL of serum using a
commercial kit (QIAamp DNA Blood mini Kit, QIAGEN)
according to the manufacturer’s instructions. Three con-
served regions of the HBV genome were amplified by
nested and heminested PCR (ORF S, ORF C, and ORF X)
according to the method described by Zeng et al [40],
Schaefer et al [41], Gunther et al [42], and Hu et al [43]. A
serum sample obtained from a patient with chronic HBV
infection was used as positive control of the assays. All as-
says were performed in duplicate.
The sensitivity of the PCR reactions for ORF S, ORF C
(preCore-Core), and ORF X was determined by serial dilu-
tions of the positive control with Fetal Bovine Serum
(FBS). The detection limit of the PCR protocol to amplify
the ORF S was 50 IU/mL while for the ORF Core and for
the ORF X was 500 IU/mL (data not shown).
The viral load was determined by real-time PCR (SsoFast
EvaGreen supermix, BIORAD) using the protocol kindly
provided by Dr. Tonya Mixson-Hayden from the Center for
Disease Control and Prevention (CDC)-Atlanta, USA. The
ORF S amplification by qPCR was performed using the
HBV425LR and HBV359F oligonucleotides described by
Mixson-Hayden [44].
Anti-HBs detection
The anti-HBs levels were determined in serum samples
using the prototype Microparticle Enzyme Immunoassay
(MEIA) and the automated Abbott AxSYM® AUSAB®.
HBV sequencing and phylogenetic assay
The amplified products were sequenced using the auto-
mated DNA sequencer BigDyeTM terminator (Macrogen,
Inc. Seoul, Korea). Sequences were evaluated with the
BLASTN (Basic Local Alignment Search Tool form the
National Center for Biotechnology Information) program
and edited using the SeqMan program (DNASTAR). The
sequences were then aligned with HBV sequences geno-
types (A to I) from GenBank (Table 3); the alignment was
performed using BioEdit [45]. Phylogenetic analyses were
performed using MEGA 5.0. For genotyping, the best
model of nucleotide substitution and the distance matrix
with the p-distance model was determined. Phylogenetic
inferences were conducted using methods of Maximum
Likelihood (ML), Maximum Parsimony (MP), Neighbor
Joining (NJ) and MrBayes. For genotype identification we
determined the best model of nucleotide substitutionwhich corresponded to the Kimura 2-parameter +Gamma
distributed (G). Phylogenetic trees were constructed using
the MEGA 5.0 program [46].
Analysis of amino acid deduced sequences
The amino acid deduced sequences of OBI cases confirmed
by sequencing were aligned with Colombian and Venezue-
lan sequences of chronic HBV infection cases of blood do-
nors subgenotype F3 reported in GenBank (Table 3). Amino
acid substitutions in the MHR of the HBsAg (aa 99-187)
and RT polymerase domain (aa rt107-rt195) were identified
using BioEdit program. Variability between groups was also
compared.
Statistical analyses
Descriptive statistics was applied using the SPSS software
(version 14.0). Measures of central tendency as mean and
the percentages were included to describe the variables.
Genetic diversity between OBI HBV sequences and
HBsAg+ reported in GenBank were compared by using
Fisher’s exact test.
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